Acylanid

NDA 9436, held by Novartis. Acetyldigitoxin.

As of Nov 15, 2026, NDA 9436 (Acylanid), held by Novartis, was not approved, with 5 approved supplements and 0 published complete response letters.

First approved: Not approved
Supplements approved: 5
Complete response letters: 0

Products

1 strengths and forms

Product	Active ingredient	Marketing
Acylanid0.1MG · tablet;oral	Acetyldigitoxin	Discontinued

All 5 submissions, including labeling and manufacturing supplements


Jan 6, 1981	Supplement 9Manufacturing · Standard review	Approved	None posted
Apr 27, 1978	Supplement 6Manufacturing · Standard review	Approved	None posted
Aug 2, 1977	Supplement 7Manufacturing · Standard review	Approved	None posted
Apr 16, 1976	Supplement 5Manufacturing · Standard review	Approved	None posted
Apr 24, 1975	Supplement 4Manufacturing · Standard review	Approved	None posted

Identifiers

Application: NDA 9436
Drugs@FDA: Overview at FDA
Company: Novartis Pharmaceuticals Corporation

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters